Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Carphenazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 5/20 | 0.72 |
| ▸ | HTR2A known ✓ | P28223 | 5/20 | 0.72 |
| ▸ | HTR2C known ✓ | P28335 | 4/20 | 0.60 |
| ▸ | HRH1 | P35367 | 9/20 | 0.72 |
| ▸ | HTR1A | P08908 | 5/20 | 0.72 |
| ▸ | ADRA2B | P18089 | 5/20 | 0.72 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.72 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.72 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.72 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.72 |
| ▸ | DRD3 | P35462 | 5/20 | 0.72 |
| ▸ | HTR2B | P41595 | 5/20 | 0.72 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.72 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.72 |
| ▸ | DRD1 | P21728 | 3/20 | 0.72 |
| ▸ | MLNR | O43193 | 1/20 | 0.72 |
| ▸ | ESR1 | P03372 | 1/20 | 0.72 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.72 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carphenazine SCHEMBL120591 | 0.94 | HRH1 (0.81) | HRH1HTR1ADRD2ADRA2BADRA2C | |
| Carphenazine SCHEMBL1458434 | 0.94 | HRH1 (0.81) | HRH1HTR1ADRD2ADRA2BADRA2C | |
| Acetophenazine SCHEMBL30903895 | 0.91 | HRH1 (0.89) | HRH1HTR1ADRD2ADRA2BADRA2C | |
| Acetophenazine SCHEMBL123789 | 0.91 | HRH1 (0.89) | HRH1HTR1ADRD2ADRA2BADRA2C | |
| Acetophenazine SCHEMBL123792 | 0.91 | HRH1 (0.89) | HRH1HTR1ADRD2ADRA2BADRA2C | |
| Acetophenazine SCHEMBL1155759 | 0.91 | HRH1 (0.89) | HRH1HTR1ADRD2ADRA2BADRA2C | |
| SCHEMBL18309819 | 0.87 | HRH1 (0.69) | HRH1HTR1ADRD2ADRA2BADRA2C | |
| Butaperazine SCHEMBL120743 | 0.86 | LMNA (0.72) | HRH1HTR1ADRD2ADRA2BADRA2C | |
| Butaperazine SCHEMBL120744 | 0.86 | LMNA (0.72) | HRH1HTR1ADRD2ADRA2BADRA2C | |
| Fumaric Acid SCHEMBL26124087 | 0.85 | HRH1 (0.61) | HRH1HTR1ADRD2ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 383 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-1044023-B1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | LUITPOLD PHARM INC (US) | 2005-05-25 | — | — | EP | claimed |
| US-6197764-B1 | COMPLEX WITH FATTY ACID; THERAPY FOR PSYCHOLOGICAL DISORDERS | PROTARGA, INC. | 2001-03-06 | — | — | US | claimed |
| EP-1044023-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | Protarga Inc. (US) | 2000-10-18 | — | — | EP | claimed |
| US-5955459-A | Fatty acid-antipsychotic compositions and uses thereof | NEUROMEDICA, INC. (US) | 1999-09-21 | — | — | US | claimed |
| WO-1999026661-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | PROTARGA INC. (US) | 1999-06-03 | — | — | WO | claimed |
| US-4690824-A | Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range | REDI-ROWELL, INC. (US) | 1987-09-01 | — | — | US | claimed |
| US-12605333-B2 | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release | TRIS PHARMA, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260096986-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A FLOATING INTERPENETRATING POLYMER NETWORK FORMING SYSTEM | TRIS PHARMA INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-3749325-B1 | DREADD ACTUATORS | US HEALTH (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| EP-0131485-B1 | SOLID PHARMACEUTICAL FORMULATIONS FOR SLOW, ZERO ORDER RELEASE VIA CONTROLLED SURFACE EROSION : EXPANDED RANGE | ROWELL LABORATORIES INCORPORATED (US) | 1990-08-29 | — | — | EP | disclosed |
| US-4690824-A | Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range | REDI-ROWELL, INC. (US) | 1987-09-01 | — | — | US | disclosed |
| EP-0212875-A2 | Medicinal composition and method of making same | Tucker, William Gough (US) | 1987-03-04 | — | — | EP | disclosed |
| US-4539198-A | Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range | ROWELL LABORATORIES, INC. (US) | 1985-09-03 | — | — | US | disclosed |
| EP-0131485-A2 | Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion : expanded range | ROWELL LABORATORIES INCORPORATED (US) | 1985-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260096986-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A FLOATING INTERPENETRATING POLYMER NETWORK FORMING SYSTEM | SI, FABP2, FABP6 | DRD2 3531/4885HTR2A 691/4885HTR2C 816/4885 |
| US-12605333-B2 | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release | SI, GRPR, FABP2 | DRD2 3220/4885HTR2A 220/4885HTR2C 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.